ライフサイエンスコーパス: rheumatism

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 self-reported, doctor-diagnosed arthritis or rheumatism.

2 study was to develop European League Against Rheumatism/American College of Rheumatology classificati

3 edicine (Incarvillea sinensis) used to treat rheumatism and pain in humans.

4 meetings of both the European League Against Rheumatism and the American College of Rheumatology was

5 ve initiative of the European League Against Rheumatism and the American College of Rheumatology.

6 tis subjects participating in the Arthritis, Rheumatism, and Aging Medical Information System (ARAMIS

7 ished RA and 38 controls, and the Arthritis, Rheumatism, and Aging Medical Information System cohort,

8 loped a Markov model based on the Arthritis, Rheumatism, and Aging Medical Information System Post-Ma

9 ast 6 months apart from 6 ARAMIS (Arthritis, Rheumatism, and Aging Medical Information System) databa

10 l patients were selected from the Arthritis, Rheumatism, and Aging Medical Information Systems databa

11 of Rheumatology, the European League Against Rheumatism, and the Outcome Measures in Rheumatology Ini

12 lege of Rheumatology (formerly, the American Rheumatism Association) 1987 criteria or all cases of se

13 lege of Rheumatology (formerly, the American Rheumatism Association) 1987 revised criteria were reque

14 lege of Rheumatology [formerly, the American Rheumatism Association] 1977 criteria) among Rochester,

15 lege of Rheumatology [formerly, the American Rheumatism Association] 1987 criteria) between 1955 and

16 lege of Rheumatology [formerly, the American Rheumatism Association]) first developed between 1955 an

17 CR) and the 2010 ACR/European League Against Rheumatism classification criteria.

18 of Rheumatology/the European League Against Rheumatism clinical classification criteria for SSc.

19 early RA who took part in the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study.

20 in 184 RA families from the UK Arthritis and Rheumatism Council Repository, each containing at least

21 ant for RA, recruited from the Arthritis and Rheumatism Council Twin Study.

22 ood responses on the European League Against Rheumatism criteria (P < 0.0001) reflected the ACR crite

23 ied according to the European League Against Rheumatism criteria for improvement in RA.

24 therapy according to European League Against Rheumatism criteria, with a sensitivity of 88.9% and a s

25 ts selected from the European League Against Rheumatism database of patients with rheumatic disorders

26 ts selected from the European League Against Rheumatism database, which comprises patients with rheum

27 f Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for rheumatoi

28 s measured using the European League Against Rheumatism (EULAR) criteria, have persistent circulating

29 e measured using the European League Against Rheumatism (EULAR) criteria.

30 ive RA, defined as a European League Against Rheumatism (EULAR) Disease Activity Score in 28 joints (

31 nse according to the European League Against Rheumatism (EULAR) response criteria (n = 505) with RA p

32 n 28 joints, and the European League against Rheumatism (EULAR) response criteria at 24 weeks.

33 s assessed using the European League Against Rheumatism (EULAR) response criteria.

34 European League Against Rheumatism (EULAR) response rates at 6 months were compa

35 ric response and the European League Against Rheumatism (EULAR) response were also determined for the

36 n 28 joints (DAS28), European League Against Rheumatism (EULAR) response, and American College of Rhe

37 28 joint counts and European League Against Rheumatism (EULAR) response.

38 nse according to the European League Against Rheumatism (EULAR) scale at week 24.

39 tology (ACR) and the European League against Rheumatism (EULAR) were assessed at week 24 (primary ana

40 Recommendations from European League Against Rheumatism (EULAR), EULAR Scleroderma Trials and Researc

41 h PAN fulfilling the European League Against Rheumatism (EULAR)/Paediatric Rheumatology European Soci

42 Rheumatology and the European League Against Rheumatism have developed new classification criteria fo

43 To discuss the European League Against Rheumatism recommendations in the management of primary

44 as defined using the European League Against Rheumatism response criteria.

45 al analyses of DAS28/European League Against Rheumatism response, and change from baseline in each pa

46 rtion meeting EULAR (European League Against Rheumatism) response criteria.

47 sponses (DAS28<2.6), European League Against Rheumatism responses, and systemic markers such as the C

48 the core measures of European League Against Rheumatism; the Hospital Anxiety and Depression Scale; d

49 culitis have led the European League Against Rheumatism to publish recommendations in the diagnosis,

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。